New hope for kids with rare swelling disorder: drug trial targets attacks

NCT ID NCT07298447

Recruiting now Disease control Sponsor: Ionis Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated May 16, 2026 · Updated 21 times

Summary

This study tests a medicine called donidalorsen in 20 children aged 2 to 12 with hereditary angioedema (HAE), a condition that causes sudden, painful swelling. The goal is to see if the drug is safe and helps reduce the number of swelling attacks. Participants receive the drug and are monitored for side effects and attack frequency.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA (HAE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Ionis Investigative Site
RECRUITING

Santa Monica, California, 90404, United States
Ionis Investigative Site
RECRUITING

St Louis, Missouri, 63141, United States
Ionis Investigative Site
RECRUITING

Cincinnati, Ohio, 45236, United States
Ionis Investigative Site
RECRUITING

Milan, 20157, Italy
Ionis Investigative Site
RECRUITING

Warsaw, 04-501, Poland
Ionis Investigative Site
RECRUITING

Barcelona, 08035, Spain

Conditions

Explore the condition pages connected to this study.

HEREDITARY ANGIOEDEMA (HAE)